Description
Cagrilintide 10 mg — Long-Acting Amylin Receptor Agonist for Weight & Metabolic Research
Cagrilintide is a long-acting analog of the peptide hormone
amylin, designed to act as an amylin receptor agonist. In
preclinical and clinical research, amylin analogs such as cagrilintide have been
investigated for roles in appetite regulation, body-weight reduction, and
glycemic control, often in combination with incretin-based agents.
What It Is
- Class: Long-acting amylin receptor agonist
- Origin concept: Based on the endogenous peptide amylin (co-secreted
with insulin from pancreatic β-cells), with structural modifications to improve
stability and half-life. - Research focus: Appetite/satiety signaling, weight management,
and complementary effects alongside GLP-1 receptor agonism.
Proposed Mechanisms (Preclinical)
Amylin Receptor Signaling
- Targets amylin receptors expressed in brain regions involved
in appetite and energy-balance regulation. - Investigated for effects on satiety, meal size, and eating frequency
in animal and human models. - Explored for delayed gastric emptying and modulation of
post-prandial glucose excursions.
Body Weight & Combination Strategies
- Preclinical and clinical research has evaluated cagrilintide for
body-weight reduction and changes in fat mass. - Frequently studied in combination with GLP-1 receptor agonists to assess
potential additive or synergistic effects on appetite and weight. - Ongoing interest in impacts on glycemic markers, liver fat, and
cardiometabolic risk factors.
Selected Research Highlights
- Obesity & Weight Management: Amylin analogs such as cagrilintide
have been examined for clinically meaningful reductions in body weight and appetite-related
endpoints. - Glycemic Control: Studies include effects on fasting glucose,
post-prandial responses, and other diabetes-related markers, particularly when combined
with incretin therapies. - Combination with GLP-1 RAs: Research has focused on the potential
for dual-pathway modulation (amylin + GLP-1) to enhance weight and
metabolic outcomes compared with monotherapy.
Chemical & Handling Information
- Type: Synthetic amylin receptor agonist (long-acting analog)
- Backbone: Modified peptide structure based on human amylin
(exact sequence and modifications per specification/lot) - Appearance: White to off-white lyophilized powder
Specifications
- Peptide: Cagrilintide
- Amount: 10 mg per vial
- Form: Lyophilized powder
- Purity: ≥99% (HPLC); COA per lot available
- Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
- Store lyophilized vials in a cool, dry place, protected from light.
- Refrigeration or freezing of the lyophilized peptide is recommended for extended stability,
according to laboratory SOPs. - After reconstitution, store at 2–8 °C for short-term use.
- For long-term storage, aliquot and freeze at −20 °C or below; avoid repeated freeze–thaw cycles.
Reviews
There are no reviews yet.